Vascular Inflammation Stratified by Body Size Phenotype

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01979068

Enrollment

250

Registered

2013-11-08

Start date

2008-03-31

Completion date

Unknown

Last updated

2013-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis, Metabolic Syndrome, Obesity

Brief summary

* Vascular Inflammation is a key factor in both the pathogenesis and outcome of atherosclerosis. 18FDG-PET is a promising novel tool for identifying and quantifying vascular inflammation within atherosclerotic plaque * Recently, unique subsets of obese individuals, such as metabolically obese but normal weight (MONW) and metabolically healthy obese (MHO), have been getting an attention * Therefore, the purpose of this study is to examine the relationship of vascular inflammation,measured by FDG-PET, with various body sized phenotypes

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy patients for visiting routine medical check in our clinic

Exclusion criteria

* history of CVD (myocardial infarction, unstable angina, stroke, or cardiovascular revascularization) * stage 2 hypertension (resting blood pressure, ≥160/100 mmHg) * history of inflammatory conditions that affect the study results * taking medications that might affect inflammatory status, including steroid and non-steroidal anti-inflammatory drug within 6 months * or malignancy or severe renal or hepatic disease

Design outcomes

Primary

Measure	Time frame
max TBR values stratified by the four body size phenotypes	12 weeks

Secondary

Measure	Time frame
Framingham risk scores according to the four body size phenotypes	12 weeks

Countries

South Korea

Outcome results